Pharmacokinetics and Safety of Human Pasteurised C1-Inhibitor Concentrate (Berinert/CE1145) in Subjects with Congenital C1-INH Deficiency.

Registry ID

EUCTR2010-019670-32

Source registry

EUCTR

Status

Ongoing

Phase

PHASE3

Sponsor

AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)

Start date

2013-01-31

Last update

2026-08-16

Conditions

• Hereditary Angioedema (HAE)

Summary

To investigate the PK profile of CE1145 in patients with weekly angioedema attacks and rapid clearance of C1-INH from plasma after normalising activation of the complement and contact system by replacing the total C1-esterase inhibitor (C1-INH) plasma pool with repetitive C1-INH administrations.

Locations

• , , Italy

Related clinical trials

• Donidalorsen Treatment in Children With Hereditary Angioedema
• A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
• Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
• Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
• A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema
• A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia

View on source registry